Eribulin Synergistically Increases Anti-Tumor Activity of an mTOR Inhibitor by Inhibiting pAKT/pS6K/pS6 in Triple Negative Breast Cancer

Unlike other breast cancer subtypes, patients with triple negative breast cancer (TNBC) have poor outcomes and no effective targeted therapies, leaving an unmet need for therapeutic targets. Efforts to profile these tumors have revealed the PI3K/AKT/mTOR pathway as a potential target. Activation of...

Descripción completa

Detalles Bibliográficos
Autores principales: Wen, Wei, Marcinkowski, Emily, Luyimbazi, David, Luu, Thehang, Xing, Quanhua, Yan, Jin, Wang, Yujun, Wu, Jun, Guo, Yuming, Tully, Dylan, Han, Ernest S., Yost, Susan E., Yuan, Yuan, Yim, John H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770784/
https://www.ncbi.nlm.nih.gov/pubmed/31480338
http://dx.doi.org/10.3390/cells8091010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770784/
https://www.ncbi.nlm.nih.gov/pubmed/31480338
http://dx.doi.org/10.3390/cells8091010

Ejemplares similares